iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) have been assigned a consensus rating of "Hold" from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $15.86.

A number of equities analysts have weighed in on ITOS shares. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Piper Sandler restated an "overweight" rating and issued a $12.00 target price (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Wedbush downgraded shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and increased their target price for the company from $10.00 to $12.00 in a research note on Wednesday, May 28th. Raymond James set a $12.00 price target on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Leerink Partnrs lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th.

Insiders Place Their Bets

In related news, CEO Michel Detheux sold 8,400 shares of the company's stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $10.10, for a total value of $84,840.00. Following the completion of the sale, the chief executive officer now directly owns 135,903 shares of the company's stock, valued at $1,372,620.30. This represents a 5.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of iTeos Therapeutics stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the completion of the transaction, the insider now owns 3,452,797 shares in the company, valued at approximately $27,829,543.82. This represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,843,142 shares of company stock worth $15,238,020 in the last quarter. 12.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Strs Ohio acquired a new position in iTeos Therapeutics in the first quarter valued at $31,000. Acadian Asset Management LLC boosted its stake in shares of iTeos Therapeutics by 14.2% during the 1st quarter. Acadian Asset Management LLC now owns 536,787 shares of the company's stock valued at $3,203,000 after buying an additional 66,641 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of iTeos Therapeutics by 117.1% in the 1st quarter. Jane Street Group LLC now owns 21,438 shares of the company's stock valued at $128,000 after acquiring an additional 147,107 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of iTeos Therapeutics during the first quarter valued at approximately $67,000. Finally, BVF Inc. IL increased its holdings in shares of iTeos Therapeutics by 32.3% in the 1st quarter. BVF Inc. IL now owns 3,075,000 shares of the company's stock worth $18,358,000 after acquiring an additional 750,000 shares during the period. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Trading Down 0.1%

Shares of NASDAQ:ITOS opened at $10.17 on Friday. iTeos Therapeutics has a 12-month low of $4.80 and a 12-month high of $18.13. The stock has a market capitalization of $389.25 million, a P/E ratio of -3.23 and a beta of 1.51. The stock's 50-day moving average price is $7.38 and its 200-day moving average price is $7.47.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, research analysts predict that iTeos Therapeutics will post -3.49 EPS for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.